Therapeutic areas
At EleaExeltis, we develop specialty therapies in oncology, hematology, rare diseases, and high-complexity conditions, with a strong focus on innovation, quality, and patient access to effective and safe treatments.
| BRAND NAME | ACTIVE INGREDIENT | INDICATION | COMMERCIALIZATION |
|---|---|---|---|
|
Abiratex
|
Abiraterone | Metastatic high-risk hormone-sensitive prostate cancer in combination with androgen deprivation therapy. |
 
|
|
Alcaf
|
Carfilzomib | Relapsed or refractory multiple myeloma. |
 
|
|
Atonox
|
Fulvestrant | Advanced or metastatic HR+ breast cancer in postmenopausal women. |
|
|
Benjor
|
Dolutegravir | Combination therapy for HIV infection. |
|
|
Bevax
|
Bevacizumab | Advanced or metastatic tumors, including colorectal, lung, glioblastoma, ovarian, renal, and cervical cancer. |
|
|
Brocabe
|
Ibrutinib | Hematologic malignancies (CLL, MCL, MZL), Waldenström macroglobulinemia, and graft-versus-host disease. |
|
|
Clonomab
|
Denosumab | An antiresorptive agent for the treatment of metastatic bone disease, giant cell tumor of bone, and hypercalcemia of malignancy. |
|
|
Drivelea
|
Abacavir + Dolutegravir + Lamivudine | Treatment of HIV-positive patients who are HLA-B*5701 negative and without hepatitis B infection. |
|
|
Elefix
|
Eribulin | Advanced breast cancer or liposarcoma. |
|
|
Everpressin
|
Terlipressin | Treatment of bleeding esophageal varices and acute hepatorenal syndrome (type 1). |
|
|
Exabant
|
Icatibant | Acute attacks of hereditary angioedema types I and II. |
|
|
Exobozan
|
cabozantinib | Advanced renal cell carcinoma or hepatocellular carcinoma as second-line treatment. |
|
|
Fedonax
|
Pirfenidone | Idiopathic pulmonary fibrosis, to slow disease progression. |
|
|
Gesnat
|
Eltrombopag | Treatment of chronic ITP and severe aplastic anemia in patients with an insufficient response to prior therapy. |
|
|
Gineva
|
Everolimus | Tumors such as HR+ breast cancer, renal cancer, TSC-related tumors, and advanced neuroendocrine tumors. |
|
|
Incox
|
Axitinib | Advanced renal cell carcinoma in adults. |
|
|
Ixomida
|
Apalutamide | Metastatic castration-sensitive or high-risk non-metastatic castration-resistant prostate cancer. |
|
|
Novex
|
Rituximab | Non-Hodgkin lymphoma, CLL, and rheumatoid arthritis. |
|
|
Pembrox
|
Pembrolizumab | Immunotherapy for multiple advanced or metastatic tumors including NSCLC, renal cancer, TNBC, cervical, endometrial cancer, and melanoma. |
|
|
Perciclib
|
Palbociclib | Advanced HR+ HER2- breast cancer. |
|
|
Regitrat
|
Bosutinib | Treatment of PH+ chronic or advanced myelogenous leukemia (CML). |
|
|
Reglicat
|
Afatinib | Locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations. |
|
|
Ricentan
|
Macitentan | Pulmonary arterial hypertension. |
|
|
Rofekxr
|
Tofacitinib | Treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PA), ulcerative colitis (UC), and polyarticular course juvenile idiopathic arthritis (pcJIA) |
|
|
Tachyben
|
Urapidil | Hypertensive emergencies and blood pressure control in perioperative and postoperative settings. |
|
|
Terfun
|
Tipiracil + Trifluridine | Metastatic colorectal cancer refractory to prior therapies or not suitable for other available treatments. |
|
|
Visedge
|
Vismodegib | Metastatic or locally advanced basal cell carcinoma. |
|
|
Zalutex
|
Enzalutamide | Advanced or metastatic prostate cancer. |
|